Evidence map›Paper›PMID 32421762›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2020

Impact of Community Treatment With Ivermectin for the Control of Scabies on the Prevalence of Antibodies to Strongyloides stercoralis in Children.

Michael Marks, Sarah Gwyn, Hilary Toloka, Christian Kositz, James Asugeni, Rowena Asugeni, Jason Diau, John M Kaldor, Lucia Romani, Michelle Redman-MacLaren and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
0.3field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Broadening the range of use cases for ivermectin - a review of the evidence.Transactions of the Royal Society of Tropical Medicine and Hygiene · 2022
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 6 institutions in 3 countries.

Michael MarksClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Sarah GwynDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Hilary TolokaAtoifi Adventist Hospital, Atoifi, Malaita Province, Solomon Islands.
Christian KositzClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
James AsugeniAtoifi Adventist Hospital, Atoifi, Malaita Province, Solomon Islands.
Rowena AsugeniAtoifi Adventist Hospital, Atoifi, Malaita Province, Solomon Islands.
Jason DiauAtoifi Adventist Hospital, Atoifi, Malaita Province, Solomon Islands.
John M KaldorKirby Institute, University of New South Wales, Sydney, Australia.
Lucia RomaniKirby Institute, University of New South Wales, Sydney, Australia.
Michelle Redman-MacLarenCollege of Medicine and Dentistry, James Cook University, Cairns, Australia.
David MacLarenCollege of Medicine and Dentistry, James Cook University, Cairns, Australia.
Anthony W SolomonClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
David C W MabeyClinical Research Department, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Andrew C SteerDepartment of Pediatrics, University of Melbourne, Melbourne, Australia.
Diana MartinDivision of Parasitic Diseases and Malaria, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Royal London Hospital · GBCenters for Disease Control and Prevention · USJames Cook University · AUUNSW Sydney · AULondon School of Hygiene & Tropical Medicine · GBRoyal Children's Hospital · AU

Funding

Wellcome Trust 102807
6 · The paper itself

Abstract

The prevalence of antibodies to Strongyloides stercoralis was measured in 0-12-year-olds using a bead-based immunoassay before and after ivermectin mass drug administration (MDA) for scabies in the Solomon Islands. Seroprevalence was 9.3% before and 5.1% after MDA (P = .019), demonstrating collateral benefits of ivermectin MDA in this setting.

Indexed as

ScabiesStrongyloides stercoralisStrongyloidiasisAnimalsChildHumansIvermectinMelanesiaPrevalenceSeroepidemiologic StudiesIvermectinivermectinneglected tropical diseasesscabiesStrongyloides

Identifiers

PMID32421762
PMCPMC7819519
OpenAlexW3027183973

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.